
Novo-Nordisk A/S D
D
NVO
46.960
USD
0.25
(0.54%)
Market Open
Volume
44,794
EPS
22
Div Yield
3.84
P/E
11
Market Cap
207,660,647,823







Market Roundup: What Happened Yesterday and What Awaits Us Today (February 10)








Market Roundup: What Happened Yesterday and What Awaits Us Today (February 4)


Novo Nordisk Shares Soar as FDA Clears First Weight-Loss Pill


Novo Nordisk Cuts 9,000 Jobs as Obesity Drug Battle Intensifies



M
R



Europe’s Biggest Companies Fall Further Behind US Rivals
Title: Novo/Nordisk A/S
Sector: Healthcare
Industry: Drug Manufacturers - General
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.